Skip to main
RANI

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Hldgs is expected to have a positive outlook due to their diverse and innovative pipeline, strong potential in key markets such as obesity and psoriasis, as well as experienced management that brings stability and expertise to the company. With a sum-of-the-parts valuation analysis indicating a $5 price target, the company has a solid foundation for growth and success, however, any potential management turnover could be a risk to monitor.

Bears say

Rani Therapeutics Hldgs is facing several significant fundamental risks, including potential commercial challenges due to a limited market share and competitive pricing pressures, as well as regulatory risks from potential FDA rejections and delays in device approvals for clinical studies. Additionally, the company may face competition from other long-acting injectable or oral delivery technologies, which could impact the success and uptake of their proprietary RaniPill platform. Furthermore, management stability and experience is crucial for a clinical-stage biotech company like Rani, and any turnover in top-level positions could disrupt or delay progress and negatively impact shareholder value.

RANI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 3 analysts, RANI has a Strong Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.